Association between polycystic ovary syndrome and metabolic syndrome

Current Medicinal Chemistry

Volumn 21, Issue 35, 2014, Pages 3999-4012

  Vélez, Leandro Martín ^a   Motta, Alicia Beatriz ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Cardiovascular disease; Diabetes; Glitazones; Hyperandrogenism; Insulin resistance; Lipids; Metabolic syndrome; Metformin; Obesity; Polycystic ovary syndrome; Simvastatin; Statins

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; ORAL CONTRACEPTIVE AGENT; ANTIDIABETIC AGENT; CYTOCHROME P450;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENETICS; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PREVALENCE; CARDIOVASCULAR DISEASES; FEMALE; LIFESTYLE; METABOLIC DISEASES; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; POLYCYSTIC OVARY SYNDROME;

ADIPOKINES; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; METABOLIC DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYCYSTIC OVARY SYNDROME;

EID: 84929086838     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140915141030     Document Type: Article

References (187)

1. Franks, S. Polycystic ovary syndrome. New Engl. J. Med., 1995, 333(13), 853-861.
2. Carmina, E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol., 2004, 56(1), 1-6.
3. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril., 2004, 81(1), 19-25.
4. Wild, R. A.; Carmina, E.; Diamanti-Kandarakis, E.; Dokras, A.; Escobar-Morreale, H. F.; Futterweit, W.; Lobo, R.; Norman, R. J.; Talbott, E.; Dumesic, D. A. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab., 2010, 95(5), 2038-2049.
5. Panidis, D.; Tziomalos, K.; Misichronis, G.; Papadakis, E.; Betsas, G.; Katsikis, I.; Macut, D. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum. Reprod., 2012, 27(2), 541-549.
6. Dunaif, A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev., 1997, 18(6), 774-800.
7. Kahn, C. R. The molecular mechanism of insulin action. Annu. Rev. Med., 1985, 36, 429-451.
8. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum. Reprod., 2012, 27(1), 14-24.
9. Alberti, K. G.; Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z.; Cleeman, J. I.; Donato, K. A.; Fruchart, J. C.; James, W. P.; Loria, C. M.; Smith, S. C., Jr.; International Diabetes Federation Task Force on, E.; Prevention; Hational Heart, L.; Blood, I.; American Heart, A.; World Heart, F.; International Atherosclerosis, S.; International Association for the Study of, O. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009, 120(16), 1640-1645.
10. Ehrmann, D. A.; Liljenquist, D. R.; Kasza, K.; Azziz, R.; Legro, R. S.; Ghazzi, M. N.; Group, P. C. T. S. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2006, 91(1), 48-53.
11. Brand, J. S.; Van Der Tweel, I.; Grobbee, D. E.; Emmelot-Vonk, M. H.; Van Der Schouw, Y. T. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol., 2011, 40(1), 189-207.
12. Garruti, G.; Depalo, R.; Vita, M. G.; Lorusso, F.; Giampetruzzi, F.; Damato, A. B.; Giorgino, F. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod. Biomed. Online., 2009, 19(4), 552-563.
13. Tziomalos, K.; Katsikis, I.; Papadakis, E.; Kandaraki, E. A.; Macut, D.; Panidis, D. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. Hum. Reprod., 2013, 28(3), 785-793.
14. De Ugarte, C. M.; Bartolucci, A. A.; Azziz, R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril., 2005, 83(5), 1454-1460.
15. Ford, E. S.; Li, C.; Sattar, N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes care, 2008, 31(9), 1898-1904.
16. Legro, R. S.; Gnatuk, C. L.; Kunselman, A. R.; Dunaif, A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin. Endocrinol. Metab., 2005, 90(6), 3236-3242.
17. Vrbikova, J.; Vondra, K.; Cibula, D.; Dvorakova, K.; Stanicka, S.; Sramkova, D.; Sindelka, G.; Hill, M.; Bendlova, B.; Skrha, J. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum. Reprod., 2005, 20(12), 3328-3332.
18. Dokras, A.; Bochner, M.; Hollinrake, E.; Markham, S.; Vanvoorhis, B.; Jagasia, D. H. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol., 2005, 106(1), 131-137.
19. Vural, B.; Caliskan, E.; Turkoz, E.; Kilic, T.; Demirci, A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum. Reprod., 2005, 20(9), 2409-2413.
20. Kershaw, E. E.; Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 2004, 89(6), 2548-2556.
21. Reverchon, M.; Rame, C.; Bertoldo, M.; Dupont, J. Adipokines and the Female Reproductive Tract. Int. J. Endocrinol., 2014, 2014, 232454.
22. Carmina, E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front. Horm. Res., 2013, 40, 40-50.
23. Chen, X.; Jia, X.; Qiao, J.; Guan, Y.; Kang, J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J. Mol. Endocrinol., 2013, 50(2), R21-37.
24. Yildizhan, R.; Ilhan, G. A.; Yildizhan, B.; Kolusari, A.; Adali, E.; Bugdayci, G. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertil. Steril., 2011, 96(1), 246-250.
25. Munir, I.; Yen, H. W.; Baruth, T.; Tarkowski, R.; Azziz, R.; Magoffin, D. A.; Jakimiuk, A. J. Resistin stimulation of 17alphahydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2005, 90(8), 4852-4857.
26. Carmina, E.; Bucchieri, S.; Mansueto, P.; Rini, G.; Ferin, M.; Lobo, R. A. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertil. Steril., 2009, 91(4 Suppl), 1332-1335.
27. Shin, H. Y.; Lee, D. C.; Lee, J. W. Adiponectin in women with polycystic ovary syndrome. Korean. J. Fam. Med., 2011, 32(4), 243-248.
28. Choi, J. H.; Rhee, E. J.; Kim, K. H.; Woo, H. Y.; Lee, W. Y.; Sung, K. C. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome. Eur. J. Endocrinol., 2011, 165(5), 789-796.
29. Tan, B. K.; Chen, J.; Farhatullah, S.; Adya, R.; Kaur, J.; Heutling, D.; Lewandowski, K. C.; O'Hare, J. P.; Lehnert, H.; Randeva, H. S. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes, 2009, 58(9), 1971-1977.
30. Svendsen, P. F.; Christiansen, M.; Hedley, P. L.; Nilas, L.; Pedersen, S. B.; Madsbad, S. Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertil. Steril., 2012, 98(1), 235-241.
31. Lecke, S. B.; Mattei, F.; Morsch, D. M.; Spritzer, P. M. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil. Steril., 2011, 95(6), 2044-2049.
32. Gautron, L.; Elmquist, J. K. Sixteen years and counting: an update on leptin in energy balance. J. Clin. Invest., 2011, 121(6), 2087-2093.
33. Carmina, E.; Chu, M. C.; Moran, C.; Tortoriello, D.; Vardhana, P.; Tena, G.; Preciado, R.; Lobo, R. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil. Steril., 2008, 89(3), 642-648.
34. Guerre-Millo, M. Adiponectin: an update. Diabetes Metab., 2008, 34(1), 12-18.
35. Curat, C. A.; Wegner, V.; Sengenes, C.; Miranville, A.; Tonus, C.; Busse, R.; Bouloumie, A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 2006, 49(4), 744-747.
36. Choi, S. H.; Kwak, S. H.; Lee, Y.; Moon, M. K.; Lim, S.; Park, Y. J.; Jang, H. C.; Kim, M. S. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin. Endocrinol. (Oxf), 2011, 75(5), 628-635.
37. Kim, S. M.; Cho, G. J.; Yannakoulia, M.; Hwang, T. G.; Kim, I. H.; Park, E. K.; Mantzoros, C. S. Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism, 2011, 60(9), 1294-1299.
38. Yamawaki, H.; Kuramoto, J.; Kameshima, S.; Usui, T.; Okada, M.; Hara, Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem. Bioph. Res. Co., 2011, 408(2), 339-343.
39. Ernst, M. C.; Sinal, C. J. Chemerin: at the crossroads of inflammation and obesity. Trends. Endocrin. Met., 2010, 21(11), 660-667.
40. Wilroy, R. S., Jr.; Givens, J. R.; Wiser, W. L.; Coleman, S. A.; Andersen, R. N.; Summitt, R. L. Hyperthecosis: an inheritable form of polycystic ovarian disease. Birth. Defects-Orig., 1975, 11(4), 81-85.
41. Franks, S.; Gharani, N.; Waterworth, D.; Batty, S.; White, D.; Williamson, R.; McCarthy, M. The genetic basis of polycystic ovary syndrome. Hum. Reprod., 1997, 12(12), 2641-2648.
42. Gharani, N.; Waterworth, D. M.; Batty, S.; White, D.; Gilling-Smith, C.; Conway, G. S.; McCarthy, M.; Franks, S.; Williamson, R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum. Mol. Genet., 1997, 6(3), 397-402.
43. Diamanti-Kandarakis, E.; Bartzis, M. I.; Bergiele, A. T.; Tsianateli, T. C.; Kouli, C. R. Microsatellite polymorphism (tttta) (n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil. Steril., 2000, 73(4), 735-741.
44. Wang, Y.; Wu, X. K.; Cao, Y. X.; Yi, L.; Zou, Y.; Qu, J. W.; Hou, L. H. Microsatellite polymorphism of (tttta) n in the promoter of CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil. Steril., 2005, 85(48), 3396-3400.
45. Gaasenbeek, M.; Powell, B. L.; Sovio, U.; Haddad, L.; Gharani, N.; Bennett, A.; Groves, C. J.; Rush, K.; Goh, M. J.; Conway, G. S.; Ruokonen, A.; Martikainen, H.; Pouta, A.; Taponen, S.; Hartikainen, A. L.; Halford, S.; Jarvelin, M. R.; Franks, S.; McCarthy, M. I. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J. Clin. Endocrinol. Metab., 2004, 89(5), 2408-2413.
46. Tan, L.; Zhu, G. Relationship between the microsatellite polymorphism of CYP11 alpha gene and the pathogenesis of hyperandrogenism of polycystic ovary syndrome in Chinese. Zhonghua yi xue yi chuan xue za zhi, 2005, 22(2), 216-218.
47. Escobar-Morreale, H. F.; San Millan, J. L.; Smith, R. R.; Sancho, J.; Witchel, S. F. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype-genotype correlations. Fertil. Steril., 1999, 72(4), 629-638.
48. Glintborg, D.; Hermann, A. P.; Brusgaard, K.; Hangaard, J.; Hagen, C.; Andersen, M. Significantly higher adrenocorticotropinstimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J. Clin. Endocrinol. Metab., 2005, 90(3), 1347-1353.
49. Wickenheisser, J. K.; Nelson-Degrave, V. L.; McAllister, J. M. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2005, 90(3), 1720-1727.
50. Gharani, N.; Waterworth, D. M.; Williamson, R.; Franks, S. 5' polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J. Clin. Endocrinol. Metab., 1996, 81(11), 4174.
51. Techatraisak, K.; Conway, G. S.; Rumsby, G. Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17, 20-lyase (CYP17) gene in hyperandrogenic states. Clin. Endocrinol. (Oxf), 1997, 46(2), 131-134.
52. Witchel, S. F.; Lee, P. A.; Suda-Hartman, M.; Smith, R.; Hoffman, E. P. 17 alpha-hydroxylase/17, 20-lyase dysregulation is not caused by mutations in the coding regions of CYP17. J. Pediatr. Adolesc. Gynecol., 1998, 11(3), 133-137.
53. Kahsar-Miller, M.; Boots, L. R.; Bartolucci, A.; Azziz, R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil. Steril., 2004, 82(4), 973-975.
54. Petry, C. J.; Ong, K. K.; Michelmore, K. F.; Artigas, S.; Wingate, D. L.; Balen, A. H.; De Zegher, F.; Ibanez, L.; Dunger, D. B. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum. Reprod., 2005, 20(7), 1837-1843.
55. Mifsud, A.; Ramirez, S.; Yong, E. L. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J. Clin. Endocrinol. Metab., 2000, 85(9), 3484-3488.
56. Pugeat, M.; Crave, J. C.; Tourniaire, J.; Forest, M. G. Clinical utility of sex hormone-binding globulin measurement. Horm. Res., 1996, 45(3-5), 148-155.
57. Waterworth, D. M.; Bennett, S. T.; Gharani, N.; McCarthy, M. I.; Hague, S.; Batty, S.; Conway, G. S.; White, D.; Todd, J. A.; Franks, S.; Williamson, R. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet, 1997, 349(9057), 986-990.
58. Urbanek, M.; Legro, R. S.; Driscoll, D. A.; Azziz, R.; Ehrmann, D. A.; Norman, R. J.; Strauss, J. F., 3rd; Spielman, R. S.; Dunaif, A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl. Acad. Sci. U S A, 1999, 96(15), 8573-8578.
59. El Mkadem, S. A.; Lautier, C.; Macari, F.; Molinari, N.; Lefebvre, P.; Renard, E.; Gris, J. C.; Cros, G.; Daures, J. P.; Bringer, J.; White, M. F.; Grigorescu, F. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes, 2001, 50(9), 2164-2168.
60. Ehrmann, D. A.; Tang, X.; Yoshiuchi, I.; Cox, N. J.; Bell, G. I. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2002, 87(9), 4297-4300.
61. Villuendas, G.; Botella-Carretero, J. I.; Roldan, B.; Sancho, J.; Escobar-Morreale, H. F.; San Millan, J. L. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and nonhyperandrogenic controls. Hum. Reprod., 2005, 20(11), 3184-3191.
62. Maes, H. H.; Neale, M. C.; Eaves, L. J. Genetic and environmental factors in relative body weight and human adiposity. Behav. Genet., 1997, 27(4), 325-351.
63. Schousboe, K.; Willemsen, G.; Kyvik, K. O.; Mortensen, J.; Boomsma, D. I.; Cornes, B. K.; Davis, C. J.; Fagnani, C.; Hjelmborg, J.; Kaprio, J.; De Lange, M.; Luciano, M.; Martin, N. G.; Pedersen, N.; Pietilainen, K. H.; Rissanen, A.; Saarni, S.; Sorensen, T. I.; Van Baal, G. C.; Harris, J. R. Sex differences in heritability of BMI: a comparative study of results from twin studies in eight countries. Twin Res., 2003, 6(5), 409-421.
64. Frayling, T. M.; Timpson, N. J.; Weedon, M. N.; Zeggini, E.; Freathy, R. M.; Lindgren, C. M.; Perry, J. R.; Elliott, K. S.; Lango, H.; Rayner, N. W.; Shields, B.; Harries, L. W.; Barrett, J. C.; Ellard, S.; Groves, C. J.; Knight, B.; Patch, A. M.; Ness, A. R.; Ebrahim, S.; Lawlor, D. A.; Ring, S. M.; Ben-Shlomo, Y.; Jarvelin, M. R.; Sovio, U.; Bennett, A. J.; Melzer, D.; Ferrucci, L.; Loos, R. J.; Barroso, I.; Wareham, N. J.; Karpe, F.; Owen, K. R.; Cardon, L. R.; Walker, M.; Hitman, G. A.; Palmer, C. N.; Doney, A. S.; Morris, A. D.; Smith, G. D.; Hattersley, A. T.; McCarthy, M. I. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science, 2007, 316(5826), 889-894.
65. Barber, T. M.; Bennett, A. J.; Groves, C. J.; Sovio, U.; Ruokonen, A.; Martikainen, H.; Pouta, A.; Hartikainen, A. L.; Elliott, P.; Lindgren, C. M.; Freathy, R. M.; Koch, K.; Ouwehand, W. H.; Karpe, F.; Conway, G. S.; Wass, J. A.; Jarvelin, M. R.; Franks, S.; McCarthy, M. I. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia, 2008, 51(7), 1153-1158.
66. Kowalska, I.; Malecki, M. T.; Straczkowski, M.; Skupien, J.; Karczewska-Kupczewska, M.; Nikolajuk, A.; Szopa, M.; Adamska, A.; Wawrusiewicz-Kurylonek, N.; Wolczynski, S.; Sieradzki, J.; Gorska, M. The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. Diabetes Metab., 2009, 35(4), 328-331.
67. Kowalska, I.; Adamska, A.; Malecki, M. T.; Karczewska-Kupczewska, M.; Nikolajuk, A.; Szopa, M.; Gorska, M.; Straczkowski, M. Impact of the FTO gene variation on fat oxidation and its potential influence on body weight in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf), 2012, 77(1), 120-125.
68. Louwers, Y. V.; Rayner, N. W.; Herrera, B. M.; Stolk, L.; Groves, C. J.; Barber, T. M.; Uitterlinden, A. G.; Franks, S.; Laven, J. S.; McCarthy, M. I. BMI-associated alleles do not constitute risk alleles for polycystic ovary syndrome independently of BMI: a casecontrol study. PloS one, 2014, 9(1), e87335.
69. Cai, X.; Liu, C.; Mou, S. Association between fat mass- and obesityassociated (FTO) gene polymorphism and polycystic ovary syndrome: a meta-analysis. PloS one, 2014, 9(1), e86972.
70. Li, T.; Wu, K.; You, L.; Xing, X.; Wang, P.; Cui, L.; Liu, H.; Cui, Y.; Bian, Y.; Ning, Y.; Zhao, H.; Tang, R.; Chen, Z. J. Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. PloS one, 2013, 8(7), e66250.
71. King, R. A.; Rotter, J. I.; Motulsky, A. G. The Genetic Basis of Common Diseases, 2nd ed.; Oxford Monographs on Medical Genetics: New York, 2002.
72. Visscher, P. M.; Hill, W. G.; Wray, N. R. Heritability in the genomics era-concepts and misconceptions. Nat. Rev. Genet., 2008, 9(4), 255-266.
73. Bouatia-Naji, N.; Rocheleau, G.; Van Lommel, L.; Lemaire, K.; Schuit, F.; Cavalcanti-Proenca, C.; Marchand, M.; Hartikainen, A. L.; Sovio, U.; De Graeve, F.; Rung, J.; Vaxillaire, M.; Tichet, J.; Marre, M.; Balkau, B.; Weill, J.; Elliott, P.; Jarvelin, M. R.; Meyre, D.; Polychronakos, C.; Dina, C.; Sladek, R.; Froguel, P. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science, 2008, 320(5879), 1085-1088.
74. Chen, Z. H.; Li, J.; Liu, J.; Zhao, Y.; Zhang, P.; Zhang, M. X.; Zhang, L. Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am. J. Chin. Med., 2008, 36(5), 939-951.
75. Do, R.; Bailey, S. D.; Desbiens, K.; Belisle, A.; Montpetit, A.; Bouchard, C.; Perusse, L.; Vohl, M. C.; Engert, J. C. Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes, 2008, 57(4), 1147-1150.
76. Freathy, R. M.; Timpson, N. J.; Lawlor, D. A.; Pouta, A.; Ben-Shlomo, Y.; Ruokonen, A.; Ebrahim, S.; Shields, B.; Zeggini, E.; Weedon, M. N.; Lindgren, C. M.; Lango, H.; Melzer, D.; Ferrucci, L.; Paolisso, G.; Neville, M. J.; Karpe, F.; Palmer, C. N.; Morris, A. D.; Elliott, P.; Jarvelin, M. R.; Smith, G. D.; McCarthy, M. I.; Hattersley, A. T.; Frayling, T. M. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes, 2008, 57(5), 1419-1426.
77. Lim, K. I.; Shin, Y. A. Impact of UCP2 polymorphism on long-term exercise-mediated changes in adipocytokines and markers of metabolic syndrome. Aging-Clin Exp. Res., 2014.
78. Rooki, H.; Haerian, M. S.; Azimzadeh, P.; Mirhafez, R.; Ebrahimi, M.; Ferns, G.; Ghayour-Mobarhan, M.; Zali, M. R. Associations between C1431T and Pro12Ala variants of PPARgamma gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population. Mol. Biol. Rep., 2014, 41(5), 3127-3133.
79. Hassanzadeh, T.; Maleki, M.; Saidijam, M.; Paoli, M. Association between leptin gene G-2548A polymorphism with metabolic syndrome. J. Res. Med. Sci., 2013, 18(8), 668-673.
80. Randeva, H. S.; Tan, B. K.; Weickert, M. O.; Lois, K.; Nestler, J. E.; Sattar, N.; Lehnert, H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr. Rev., 2012, 33(5), 812-841.
81. Diamanti-Kandarakis, E.; Spina, G.; Kouli, C.; Migdalis, I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol. Metab., 2001, 86(10), 4666-4673.
82. Cascella, T.; Palomba, S.; Tauchmanova, L.; Manguso, F.; Di Biase, S.; Labella, D.; Giallauria, F.; Vigorito, C.; Colao, A.; Lombardi, G.; Orio, F. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab., 2006, 91(11), 4395-4400.
83. Elting, M. W.; Korsen, T. J.; Bezemer, P. D.; Schoemaker, J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum. Reprod., 2001, 16(3), 556-560.
84. Vrbikova, J.; Cifkova, R.; Jirkovska, A.; Lanska, V.; Platilova, H.; Zamrazil, V.; Starka, L. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum. Reprod., 2003, 18(5), 980-984.
85. Sprung, V. S.; Jones, H.; Pugh, C. J.; Aziz, N. F.; Daousi, C.; Kemp, G. J.; Green, D. J.; Cable, N. T.; Cuthbertson, D. J. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin. Sci., 2014, 126(1), 67-74.
86. Holte, J.; Gennarelli, G.; Berne, C.; Bergh, T.; Lithell, H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum. Reprod., 1996, 11(1), 23-28.
87. Orbetzova, M. M.; Shigarminova, R. G.; Genchev, G. G.; Milcheva, B. A.; Lozanov, L. B.; Genov, N. S.; Zacharieva, S. Z. Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome. Folia med., 2003, 45(3), 21-25.
88. Wild, S.; Pierpoint, T.; McKeigue, P.; Jacobs, H. Cardiovascular disease in women with polycystic ovary syndrome at long-term followup: a retrospective cohort study. Clin. Endocrinol. (Oxf), 2000, 52(5), 595-600.
89. Glueck, C. J.; Morrison, J. A.; Goldenberg, N.; Wang, P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism, 2009, 58(5), 714-721.
90. Talbott, E. O.; Zborowski, J. V.; Rager, J. R.; Boudreaux, M. Y.; Edmundowicz, D. A.; Guzick, D. S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2004, 89(11), 5454-5461.
91. Hollinrake, E.; Abreu, A.; Maifeld, M.; Van Voorhis, B. J.; Dokras, A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil. Steril., 2007, 87(6), 1369-1376.
92. Barnard, L.; Ferriday, D.; Guenther, N.; Strauss, B.; Balen, A. H.; Dye, L. Quality of life and psychological well being in polycystic ovary syndrome. Hum. Reprod., 2007, 22(8), 2279-2286.
93. Pamuk, B. O.; Torun, A. N.; Kulaksizoglu, M.; Ertugrul, D.; Ciftci, O.; Kulaksizoglu, S.; Yildirim, E.; Demirag, N. G. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil. Steril., 2010, 93(4), 1227-1233.
94. Arad, Y.; Spadaro, L. A.; Goodman, K.; Lledo-Perez, A.; Sherman, S.; Lerner, G.; Guerci, A. D. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation, 1996, 93(11), 1951-1953.
95. Shroff, R.; Kerchner, A.; Maifeld, M.; Van Beek, E. J.; Jagasia, D.; Dokras, A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J. Clin. Endocrinol. Metab., 2007, 92(12), 4609-4614.
96. Orio, F., Jr.; Palomba, S.; Cascella, T.; De Simone, B.; Di Biase, S.; Russo, T.; Labella, D.; Zullo, F.; Lombardi, G.; Colao, A. Early impairment of endothelial structure and function in young normalweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2004, 89(9), 4588-4593.
97. Prelevic, G. M.; Beljic, T.; Balint-Peric, L.; Ginsburg, J. Cardiac flow velocity in women with the polycystic ovary syndrome. Clin. Endocrinol. (Oxf), 1995, 43(6), 677-681.
98. Orio, F., Jr.; Palomba, S.; Spinelli, L.; Cascella, T.; Tauchmanova, L.; Zullo, F.; Lombardi, G.; Colao, A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab., 2004, 89(8), 3696-3701.
99. Yarali, H.; Yildirir, A.; Aybar, F.; Kabakci, G.; Bukulmez, O.; Akgul, E.; Oto, A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil. Steril., 2001, 76(3), 511-516.
100. Trakakis, E.; Balanika, A.; Baltas, C.; Loghis, C.; Simeonidis, G.; Vaggopoulos, V.; Papakonstantinou, O.; Gouliamos, A.; Salamalekis, G.; Kassanos, D. Hemodynamic alterations and wall properties in large arteries of young, normotensive, and non-obese women with polycystic ovary syndrome. J. Endocrinol. Invest., 2008, 31(11), 1001-1007.
101. Soares, G. M.; Vieira, C. S.; Martins, W. P.; Franceschini, S. A.; Dos Reis, R. M.; Silva De Sa, M. F.; Ferriani, R. A. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin. Endocrinol. (Oxf), 2009, 71(3), 406-411.
102. Vinik, A. I.; Erbas, T.; Park, T. S.; Nolan, R.; Pittenger, G. L. Platelet dysfunction in type 2 diabetes. Diabetes care, 2001, 24(8), 1476-1485.
103. Quinonez Zarza, C.; Silva Ruiz, R.; Torres Juarez, J. M. [Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome]. Ginecol. Obstet. Méx., 2000, 68, 317-322.
104. Kelly, C. C.; Lyall, H.; Petrie, J. R.; Gould, G. W.; Connell, J. M.; Sattar, N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab., 2001, 86(6), 2453-2455.
105. Yildiz, B. O.; Haznedaroglu, I. C.; Kirazli, S.; Bayraktar, M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metab., 2002, 87(8), 3871-3875.
106. Heutling, D.; Schulz, H.; Nickel, I.; Kleinstein, J.; Kaltwasser, P.; Westphal, S.; Mittermayer, F.; Wolzt, M.; Krzyzanowska, K.; Randeva, H.; Schernthaner, G.; Lehnert, H. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J. Clin. Endocrinol. Metab., 2008, 93(1), 82-90.
107. Gomes, V. A.; Vieira, C. S.; Jacob-Ferreira, A. L.; Belo, V. A.; Soares, G. M.; Fernandes, J. B.; Ferriani, R. A.; Tanus-Santos, J. E. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Mol. Cell. Biochem., 2011, 353(1-2), 251-257.
108. Orbe, J.; Fernandez, L.; Rodriguez, J. A.; Rabago, G.; Belzunce, M.; Monasterio, A.; Roncal, C.; Paramo, J. A. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003, 170(2), 269-276.
109. Goncalves, F. M.; Jacob-Ferreira, A. L.; Gomes, V. A.; Casella-Filho, A.; Chagas, A. C.; Marcaccini, A. M.; Gerlach, R. F.; Tanus-Santos, J. E. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin. Chim. Acta., 2009, 403(1-2), 173-177.
110. Grundy, S. M.; Brewer, H. B., Jr.; Cleeman, J. I.; Smith, S. C., Jr.; Lenfant, C.; National Heart, L.; Blood, I.; American Heart, A. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscl. Throm. Vas., 2004, 24(2), e13-18.
111. Isomaa, B.; Almgren, P.; Tuomi, T.; Forsen, B.; Lahti, K.; Nissen, M.; Taskinen, M. R.; Groop, L., Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes care, 2001, 24(4), 683-689.
112. Shaw, D. I.; Hall, W. L.; Williams, C. M. Metabolic syndrome: what is it and what are the implications? P. Nutr. Soc., 2005, 64(3), 349-357.
113. Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z. The metabolic syndrome. Lancet, 2005, 365(9468), 1415-1428.
114. Azizi, F.; Salehi, P.; Etemadi, A.; Zahedi-Asl, S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res. Clin. Pr., 2003, 61(1), 29-37.
115. Paoletti, R.; Bolego, C.; Poli, A.; Cignarella, A. Metabolic syndrome, inflammation and atherosclerosis. Vasc. Health Risk Manag., 2006, 2(2), 145-152.
116. Gami, A. S.; Witt, B. J.; Howard, D. E.; Erwin, P. J.; Gami, L. A.; Somers, V. K.; Montori, V. M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49(4), 403-414.
117. Birk, R. Z.; Rubio-Aliaga, I.; Boekschoten, M. V.; Danino, H.; Muller, M.; Daniel, H. Differential regulation of pancreatic digestive enzymes during chronic high-fat diet-induced obesity in C57BL/6J mice. Brit. J. Nutr., 2014, 112(2), 154-161.
118. Mirzaei, K.; Hossein-Nezhad, A.; Keshavarz, S. A.; Eshaghi, S. M.; Koohdani, F.; Saboor-Yaraghi, A. A.; Hosseini, S.; Tootee, A.; Djalali, M. Insulin resistance via modification of PGC1alpha function identifying a possible preventive role of vitamin D analogues in chronic inflammatory state of obesity. A double blind clinical trial study. Minerva Med., 2014, 105(1), 63-78.
119. Ivey, R.; Desai, M.; Green, K.; Sinha-Hikim, I.; Friedman, T. C.; Sinha-Hikim, A. P. Additive Effects of Nicotine and High-Fat Diet on Hepatocellular Apoptosis in Mice: Involvement of Caspase 2 and Inducible Nitric Oxide Synthase-Mediated Intrinsic Pathway Signaling. Horm. Metab. Res., 2014, 46(8), 568-573.
120. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; O'Reilly, D. S.; Haffner, S. M.; Isles, C.; Macfarlane, P. W.; Packard, C. J.; Cobbe, S. M.; Shepherd, J. Metabolic syndrome with and without Creactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 2003, 108(4), 414-419.
121. Mottillo, S.; Filion, K. B.; Genest, J.; Joseph, L.; Pilote, L.; Poirier, P.; Rinfret, S.; Schiffrin, E. L.; Eisenberg, M. J. The metabolic syndrome and cardiovascular risk a systematic review and metaanalysis. J. Am. Coll. Cardiol., 2010, 56(14), 1113-1132.
122. Vassilatou, E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J. Gastroentero., 2014, 20(26), 8351-8363.
123. Angulo, P. Nonalcoholic fatty liver disease. New Engl. J. Med., 2002, 346(16), 1221-1231.
124. Marchesini, G.; Brizi, M.; Morselli-Labate, A. M.; Bianchi, G.; Bugianesi, E.; McCullough, A. J.; Forlani, G.; Melchionda, N. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med., 1999, 107(5), 450-455.
125. Bugianesi, E.; Gastaldelli, A.; Vanni, E.; Gambino, R.; Cassader, M.; Baldi, S.; Ponti, V.; Pagano, G.; Ferrannini, E.; Rizzetto, M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia, 2005, 48(4), 634-642.
126. Kotronen, A.; Yki-Jarvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arteriosc.l Throm. Vas., 2008, 28(1), 27-38.
127. Chitturi, S.; Abeygunasekera, S.; Farrell, G. C.; Holmes-Walker, J.; Hui, J. M.; Fung, C.; Karim, R.; Lin, R.; Samarasinghe, D.; Liddle, C.; Weltman, M.; George, J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 2002, 35(2), 373-379.
128. Matteoni, C. A.; Younossi, Z. M.; Gramlich, T.; Boparai, N.; Liu, Y. C.; McCullough, A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 1999, 116(6), 1413-1419.
129. Brown, A. J.; Tendler, D. A.; McMurray, R. G.; Setji, T. L. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr. Pract., 2005, 11(5), 319-324.
130. Adams, L. A.; Talwalkar, J. A. Diagnostic evaluation of nonalcoholic fatty liver disease. J. Clin. Gastroenterol., 2006, 40 Suppl 1, S34-38.
131. Schwimmer, J. B.; Khorram, O.; Chiu, V.; Schwimmer, W. B. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil. Steril., 2005, 83(2), 494-497.
132. Setji, T. L.; Holland, N. D.; Sanders, L. L.; Pereira, K. C.; Diehl, A. M.; Brown, A. J. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2006, 91(5), 1741-1747.
133. Barfield, E.; Liu, Y. H.; Kessler, M.; Pawelczak, M.; David, R.; Shah, B. The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol., 2009, 22(5), 318-322.
134. Prati, D.; Taioli, E.; Zanella, A.; Della Torre, E.; Butelli, S.; Del Vecchio, E.; Vianello, L.; Zanuso, F.; Mozzi, F.; Milani, S.; Conte, D.; Colombo, M.; Sirchia, G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med., 2002, 137(1), 1-10.
135. Sprung, V. S.; Cuthbertson, D. J.; Pugh, C. J.; Aziz, N.; Kemp, G. J.; Daousi, C.; Green, D. J.; Tim Cable, N.; Jones, H. Exercise Training in PCOS Enhances FMD in the Absence of Changes in Fatness. Med. Sci. Sports Exerc., 2013, 45(12), 2234-2242.
136. Nybacka, A.; Carlstrom, K.; Fabri, F.; Hellstrom, P. M.; Hirschberg, A. L. Serum antimullerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Fertil. Steril., 2013, 100(4), 1096-1102.
137. Lass, N.; Kleber, M.; Winkel, K.; Wunsch, R.; Reinehr, T. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J. Clin. Endocrinol. Metab., 2011, 96(11), 3533-3540.
138. Uemura, H.; Katsuura-Kamano, S.; Yamaguchi, M.; Nakamoto, M.; Hiyoshi, M.; Arisawa, K. Abundant daily non-sedentary activity is associated with reduced prevalence of metabolic syndrome and insulin resistance. J. Endocrinol. Invest., 2013, 36(11), 1069-1075.
139. Moran, L. J.; Ko, H.; Misso, M.; Marsh, K.; Noakes, M.; Talbot, M.; Frearson, M.; Thondan, M.; Stepto, N.; Teede, H. J. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. Hum. Reprod. Update, 2013, 113(4), 520-545.
140. Colpani, V.; Oppermann, K.; Spritzer, P. M. Association between habitual physical activity and lower cardiovascular risk in premenopausal, perimenopausal, and postmenopausal women: a population-based study. Menopause, 2013, 20(5), 525-531.
141. Richette, P.; Perez-Ruiz, F. Serum uric acid and metabolic risk. Curr Med Res Opin, 2013, 29(3), 9-15.
142. Chiu, K. C.; Chu, A.; Go, V. L.; Saad, M. F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr., 2004, 79(5), 820-825.
143. Isaia, G.; Giorgino, R.; Adami, S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care, 2001, 24(8), 1496.
144. Freundlich, M.; Quiroz, Y.; Zhang, Z.; Zhang, Y.; Bravo, Y.; Weisinger, J. R.; Li, Y. C.; Rodriguez-Iturbe, B. Suppression of reninangiotensin gene expression in the kidney by paricalcitol. Kidney Int., 2008, 74(11), 1394-1402.
145. Hahn, S.; Haselhorst, U.; Tan, S.; Quadbeck, B.; Schmidt, M.; Roesler, S.; Kimmig, R.; Mann, K.; Janssen, O. E. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes, 2006, 114(10), 577-583.
146. Bargiota, A.; Diamanti-Kandarakis, E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther. Adv. Endocrinol. Metab., 2012, 3(1), 27-47.
147. Kaya, C.; Cengiz, S. D.; Satiroglu, H. Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS. Reprod. Biomed. Online, 2009, 19(5), 721-726.
148. Goldberg, T.; Cai, W.; Peppa, M.; Dardaine, V.; Baliga, B. S.; Uribarri, J.; Vlassara, H. Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc., 2004, 104(8), 1287-1291.
149. Diamanti-Kandarakis, E.; Katsikis, I.; Piperi, C.; Kandaraki, E.; Piouka, A.; Papavassiliou, A. G.; Panidis, D. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf), 2008, 69(4), 634-641.
150. Glueck, C. J.; Streicher, P.; Wang, P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert. Opin. Pharmacother., 2002, 3(8), 1177-1189.
151. Kalkhoff, R. K. Effects of oral contraceptive agents on carbohydrate metabolism. J. Steroid Biochem., 1975, 6(6), 949-956.
152. Gaspard, U.; Scheen, A.; Endrikat, J.; Buicu, C.; Lefebvre, P.; Gerlinger, C.; Heithecker, R. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception, 2003, 67(6), 423-429.
153. Vrbikova, J.; Stanicka, S.; Dvorakova, K.; Hill, M.; Vondra, K.; Bendlova, B.; Starka, L. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur. J. Endocrinol., 2004, 150(2), 215-223.
154. Rautio, K.; Tapanainen, J. S.; Ruokonen, A.; Morin-Papunen, L. C. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur. J. Endocrinol., 2005, 152(2), 269-275.
155. Ozdemir, S.; Gorkemli, H.; Gezginc, K.; Ozdemir, M.; Kiyici, A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int. J. Gynaecol. Obstet., 2008, 103(1), 44-49.
156. Morin-Papunen, L.; Vauhkonen, I.; Koivunen, R.; Ruokonen, A.; Martikainen, H.; Tapanainen, J. S. Metformin versus ethinyl estradiolcyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab., 2003, 88(1), 148-156.
157. Mastorakos, G.; Koliopoulos, C.; Creatsas, G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril., 2002, 77(5), 919-927.
158. Luque-Ramirez, M.; Alvarez-Blasco, F.; Botella-Carretero, J. I.; Martinez-Bermejo, E.; Lasuncion, M. A.; Escobar-Morreale, H. F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2007, 92(7), 2453-2461.
159. Lemay, A.; Dodin, S.; Turcot, L.; Dechene, F.; Forest, J. C. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum. Reprod., 2006, 21(1), 121-128.
160. Hoeger, K.; Davidson, K.; Kochman, L.; Cherry, T.; Kopin, L.; Guzick, D. S. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab., 2008, 93(11), 4299-4306.
161. Harborne, L.; Fleming, R.; Lyall, H.; Sattar, N.; Norman, J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2003, 88(9), 4116-4123.
162. Cibula, D.; Fanta, M.; Vrbikova, J.; Stanicka, S.; Dvorakova, K.; Hill, M.; Skrha, J.; Zivny, J.; Skrenkova, J. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum. Reprod., 2005, 20(1), 180-184.
163. Guido, M.; Romualdi, D.; Giuliani, M.; Suriano, R.; Selvaggi, L.; Apa, R.; Lanzone, A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab., 2004, 89(6), 2817-2823.
164. Nader, S.; Diamanti-Kandarakis, E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod., 2007, 22(2), 317-322.
165. Vrbikova, J.; Cibula, D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum. Reprod. Update, 2005, 11(3), 277-291.
166. Korytkowski, M. T.; Mokan, M.; Horwitz, M. J.; Berga, S. L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1995, 80(11), 3327-3334.
167. Baillargeon, J. P.; Iuorno, M. J.; Nestler, J. E. Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol., 2003, 46(2), 325-340.
168. Diamanti-Kandarakis, E.; Christakou, C. D.; Kandaraki, E.; Economou, F. N. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur. J. Endocrinol., 2010, 162(2), 193-212.
169. Al-Nozha, O.; Habib, F.; Mojaddidi, M.; El-Bab, M. F. Body weight reduction and metformin: Roles in polycystic ovary syndrome. Pathophysiology, 2013, 20(2), 131-137.
170. Hoffmann, I. S.; Cubeddu, L. X. Association of Traits of Metabolic Syndrome With Glucose Abnormalities. Am. J. Ther., 2013, 20(4), 363-368.
171. Elia, E. M.; Pustovrh, C.; Amalfi, S.; Devoto, L.; Motta, A. B. Link between metformin and the peroxisome proliferator-activated receptor gamma pathway in the uterine tissue of hyperandrogenized prepubertal mice. Fertil. Steril., 2011, 95(8), 2534-2537 e2531.
172. Diamanti-Kandarakis, E.; Mitrakou, A.; Raptis, S.; Tolis, G.; Duleba, A. J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 1998, 83(8), 2699-2705.
173. Sahin, Y.; Unluhizarci, K.; Yilmazsoy, A.; Yikilmaz, A.; Aygen, E.; Kelestimur, F. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf), 2007, 67(6), 904-908.
174. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
175. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990, 347(6294), 645-650.
176. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68(5), 879-887.
177. Komar, C. M. Peroxisome proliferator-activated receptors (PPARs) and ovarian function-implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod. Biol. Endocrinol., 2005, 3, 41.
178. Faut, M.; Elia, E. M.; Parborell, F.; Cugnata, N. M.; Tesone, M.; Motta, A. B. Peroxisome proliferator-activated receptor gamma and early folliculogenesis during an acute hyperandrogenism condition. Fertil. Steril., 2011, 95(1), 333-337.
179. Heber, M. F.; Ferreira, S. R.; Velez, L. M.; Motta, A. B. Prenatal hyperandrogenism and lipid profile during different age stages: an experimental study. Fertil. Steril., 2013, 99(2), 551-557.
180. Velez, L. M.; Abruzzese, G. A.; Motta, A. B. The Biology of the Peroxisome Proliferator-activated Receptor System in the Female Reproductive Tract. Curr. Pharm. Des., 2013, 19(25), 4641-4646.
181. Nissen, S. E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356(24), 2457-2471.
182. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D. P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des., 2013, 19(17), 3124-3131.
183. Hugues, J. N.; Cedrin-Durnerin, I.; Howles, C. M.; Amram, M.; Angelini, A.; Balen, A.; Barbereau, D.; Birkhauser, M.; Boujenah, A.; De Leo, V.; De Placido, G.; Dessole, S.; Favrin, S.; Ferrazi, E.; Gay, C.; Germond, M.; Hedon, B.; Hocke, C.; Jolly, C.; Lamarca-Roth, E.; Lanzone, A.; Marchand, F.; Marcolin, G.; Mascaretti, G.; Moreau, L.; Massobrio, M.; Nappi, C.; Pardi, G.; Pennehouat, G.; Porcu, E.; Seibert, M.; Selvaggi, L.; Thiers, D.; Venturini, P. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study. Hum. Reprod., 2006, 21(11), 2817-2822.
184. Banaszewska, B.; Pawelczyk, L.; Spaczynski, R. Z.; Dziura, J.; Duleba, A. J. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J. Clin. Endocrinol. Metab., 2007, 92(2), 456-461.
185. Rizzo, M.; Berneis, K.; Carmina, E.; Rini, G. B. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am. J. Obstet. Gynecol., 2008, 198(1), 28 e21-25.
186. Gao, L.; Zhao, F. L.; Li, S. C. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials. Exp. Clin. Endocrinol. Diabetes., 2012, 120(6), 367-375.
187. Mikus, C. R.; Boyle, L. J.; Borengasser, S. J.; Oberlin, D. J.; Naples, S. P.; Fletcher, J.; Meers, G. M.; Ruebel, M.; Laughlin, M. H.; Dellsperger, K. C.; Fadel, P. J.; Thyfault, J. P. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol., 2013, 62(8), 709-714.